Ruti Aga banned for six years: a forged prescription written by a family member ends an elite marathon career

Ethiopian marathon runner Ruti Aga has been handed a six-year ban for breaches of anti-doping rules, the Athletics Integrity Unit (AIU) announced on Thursday. The sanction, dated from 10 September, covers two separate violations: the presence of a prohibited substance and tampering with the investigative process. At 32, Aga will be nearly 38 by the time the ban expires.

Three separate verification checks failed. The clinic named on the prescription does not exist. The 'doctor' who signed it is a family member with no medical registration. And the person claimed to have used an old prescription pad from a former workplace — a claim that workplace itself rejected. One document, three independent collapses. That is why the panel treated the matter as full tampering rather than a failure of cooperation.

The arithmetic of the sanction

The six years break down as two years for the presence violation plus four for tampering. That structure is telling. A two-year ban is the standard outcome where a Specified Substance is found and intent is not established, and it remains open to reduction where an athlete can show no fault or no significant fault. A total of six years indicates the panel declined to apply any such mitigation. The four-year tampering sanction is the Code's default, not an escalation. The loss came from the failure to reduce the base sanction — and that failure was caused by the method of defence, not the substance.

The backdating to 10 September is procedural, not lenient. Time already served under provisional suspension counts against the ban. In practical terms, the athlete gained nothing.

What the substance actually is

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, listed under class S9 of the WADA Prohibited List, and S9 glucocorticoids are prohibited in-competition only, by injection, oral or rectal routes. Out-of-competition therapeutic use is entirely legal.

The distinction is decisive. The case turned on route of administration and timing relative to the race, not on 'steroid use'. Intra-articular methylprednisolone for knee synovitis is standard sports medicine in distance running. A properly documented treatment, with genuine hospital records, a real physician and a correct washout period, gave Aga a legitimate — if not guaranteed — defence. By fabricating the prescription she destroyed the one argument that could have reduced the sanction.

There is an added irony: glucocorticoids have no established endurance benefit. They reduce pain and inflammation; they do not make a marathoner faster. The size of this sanction was determined by process, not by pharmacological gain.

The injury is the root cause

Aga cited a knee injury, and the explanation is mechanistically plausible. Chronic knee pathology is a known structural failure mode in high-volume marathoners. But the question is how the injury was managed. A properly supported athlete either holds or applies for a Therapeutic Use Exemption, or observes the route-specific washout period and schedules races accordingly. Neither happened. A third route was taken: the paper trail was manufactured.

That points to an absent or informal medical structure around the athlete. The 'doctor' was a relative with no registration. This is a systemic signal, not merely an individual lapse. Injured marathoners face strong incentives to mask pain in order to protect appearance-fee income; glucocorticoids are the cheapest and most available tool for that; and the surrounding medical network is informal and unaccountable. The forgery sits downstream of a governance gap.

The career ledger

Aga is a genuinely elite marathoner. Her headline result is victory at the 2026 Tokyo Marathon, a World Marathon Major, alongside three second-place finishes at Majors. That is a profile few athletes in any decade can match.

Importantly, the violation is anchored to the March race. Absent a finding of earlier use, earlier results — including the 2026 Tokyo title — are not automatically annulled. The report does not state the disqualification scope, but standard AIU practice voids the competition at which the sample was collected, along with its prize money and ranking points accrued thereafter. That almost certainly removes the March win itself.

What six years means

Six years out of competitive racing is, for elite purposes, a lifetime ban. Marathon performance depends on continuity of load, rhythm and racing experience. A six-year gap cannot be bridged at 38 in a system as deep as Ethiopia's. Her removal changes nothing in Ethiopian selection calculus — the national pool runs several layers deep below world-record class, and Aga held no global championship medal. The competitive landscape is unaffected. The governance landscape is the real subject.

The China label-race circuit

The March race was a half marathon in China, presumably a World Athletics Label road race. Asian label races have become a lucrative, low-risk income tier for East African marathoners between Majors: reasonable appearance fees, modest competitive pressure. That same tier is now the AIU's highest-yield testing ground. Where money is good, fields are deep and administrative oversight is thinner, anti-doping resources concentrate. The appearance-fee economy and the testing economy are colliding in the same races.

Aga's case belongs to a recognisable family of East African road-racing cases in which an initial substance violation is compounded by a fabricated or altered explanation. The enforcement frontier has shifted from detection to document verification.

Appeal and open questions

A CAS appeal window exists, typically around three weeks from the reasoned decision. The prospects are poor: the forgery finding rests on documentary evidence — a non-existent clinic, an unregistered signatory, a disowned pad — not on testimony or interpretation. Any viable appeal would target the length of the sanction or the scope of disqualification, not the finding itself.

Three things are conspicuously absent from the reporting: the winning mark from the March half marathon; the year of the race and of the ban's start; and the precise disqualification scope. Filling those gaps with invented numbers would replicate the very error at the centre of this story.

The proportionality debate

This case will be cited on both sides. For the AIU, it demonstrates that tampering carries a heavy price regardless of the substance involved. For critics, a six-year ban for a glucocorticoid with no proven endurance benefit — imposed on an athlete operating inside an informal medical network — will read as evidence of aggressive enforcement against African road runners. Ethiopian federation reaction is not quoted anywhere in the report; only the AIU statement exists.

The facts are narrower than either argument. The six years were triggered by the forgery, not by the injection. Had Aga said nothing, she would today be looking at a two-year absence and a possible return at 34. Instead, a career that included a Major title ends with a forged prescription written by a family member.